| Data | Títol | Autor(s) | Tipus | | 2023 | LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA. | Rosinol, Laura; Oriol, Albert; Rios, Rafael; Blanchard, Maria Jesus; Jarque, Isidro; Bargay, Joan; Hernandez, Miguel Teodoro; Cabanas, Valentin; Carrillo-Cruz, Estrella; Sureda, Anna; Martinez-Lopez, Joaquin; Krsnik, Isabel; Gonzalez, Maria Esther; Casado, Luis Felipe; Marti, Josep Maria; Encinas, Cristina; de Arriba, Felipe; Palomera, Luis; Sampol, Antonia; Gonzalez-Montes, Yolanda; Cabezudo, Elena; Paiva, Bruno; Puig, Noemi; Cedena, Maria Teresa; de la Cruz, Javier; Mateos, Maria-Victoria; San Miguel, Jesus; Lahuerta, Juan Jose; Blade, Joan | Article |
| 2023 | Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma. | Ferra Coll C, Morgades de la Fe M, García LP, Vaz CP, Heras Fernando MI, Bailen Almorox R, Garcia Cadenas I, Calabuig Muñoz M, Ripa TZ, Zanabili Al-Sibai J, Novoa S, Aguado Bueno B, Torrent Catarineu A, López-Godino O, Martino Bofarull R, Kwon M, Júnior AC, Caballero Barrigón D, Ribera Santasusana JM. | Article |
| 2022 | Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma | Tamariz-Amador, LE; Rodriguez-Otero, P; Jimenez-Ubieto, A; Rosinol, L; Oriol, A; Rios, R; Sureda, A; Blanchard, MJ; Hernandez, MT; Perianes, VC; Jarque, I; Bargay, J; Gironella, M; De Arriba, F; Palomera, L; Gonzalez-Montes, Y; Marti, JM; Krsnik, I; Arguinano, JM; Gonzalez, ME; Casado, LF; Gonzalez-Rodriguez, AP; Lopez-Anglada, L; Puig, N; Cedena, MT; Paiva, B; Mateos, MV; San-Miguel, J; Lahuerta, JJ; Blade, J; Troconiz, IF | Article |
| 2022 | Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas | Moreno DF; Clapés V; Soler JA; González-Montes Y; Gironella M; Motlló C; Granell M; Abella E; García-Pintos M; García-Guiñon A; Cabezudo E; Bladé J; Rosiñol L* | Article |
| 2022 | A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma | Encinas C; Hernandez-Rivas JÁ; Oriol A; Rosiñol L; Blanchard MJ; Bellón JM; García-Sanz R; de la Rubia J; de la Guía AL; Jímenez-Ubieto A; Jarque I; Iñigo B; Dourdil V; de Arriba F; Pérez-Ávila CC; Gonzalez Y; Hernández MT; Bargay J; Granell M; Rodríguez-Otero P; Silvent M; Cabrera C; Rios R; Alegre A; Gironella M; Gonzalez MS; Sureda A; Sampol A; Ocio EM; Krsnik I; García A; García-Mateo A; Soler JA; Martín J; Arguiñano JM; Mateos MV; Bladé J; San-Miguel JF; Lahuerta JJ; Martínez-López J; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group | Article |
| 2022 | Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study | Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez E, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández A, Naves A, Rosiñol L | Article |
| 2022 | Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S; Montes YG | Article |
| 2021 | Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma | Cejalvo MJ; Bustamante G; González E; Vázquez-Álvarez J; Garcia R; Ramírez-Payer Á; Pérez-Persona E; Abella E; Garzón S; Garcia A; Jarque I; González MS; Sampol A; Motlló C; Martí JM; Alcalá M; Duro R; González Y; Sastre JL; Sarrà J; Lostaunau G; Lopez R; de la Rubia J* | Article |
| 2021 | Trends of incidence; mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study | Chang-Chan DY; Ríos-Tamayo R; Rodríguez Barranco M; Redondo-Sánchez D; González Y; Marcos-Gragera R; Sánchez MJ. | Article |
| 2019 | Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma | Rosinol, L.; Oriol, A.; Rios, R.; Sureda, A.; Blanchard, M.J.; Hernández, M.T.; Martínez-Martínez, R.; Moraleda, J.M.; Jarque, I.; Bargay, J.; Gironella, M.; de Arriba, F.; Palomera, L.; Gonzalez-Montes, Y.; Martí, J.; Krsnik, I.; Arguiñano, J.M.; González, M.E.; Gonzalez, A.P.; Casado, L.F.; Lopez-Anglada, L.; Paiva, B.; Mateos, M.V.; San Miguel, J.; Lahuerta, J.J.; Blade J. | Article |
| 2019 | Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents? | Gassiot, S; Gonzalez, Y; Morgades, M; Motllo, C; Clapes, V; Maluquer, C; Ibarra, G; Abril, L; Ribera, JM; Oriol, A | Article |
| 2019 | Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. | Rodriguez-Otero, P; Mateos, MV; Martinez-Lopez, J; Hernandez, MT; Ocio, EM; Rosinol, L; Martinez, R; Teruel, AI; Gutierrez, NC; Bargay, J; Bengoechea, E; Gonzalez, Y; de Oteyza, JP; Gironella, M; Nunez-Cordoba, JM; Encinas, C; Martin, J; Cabrera, C; Palomera, L; de Arriba, F; Cedena, MT; Puig, N; Oriol, A; Paiva, B; Blade, J; Lahuerta, JJ; San Miguel, JF | Article |
| 2018 | Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role | Rodriguez-Otero, P; Mateos, MV; Martinez-Lopez, J; Martin-Calvo, N; Hernandez, MT; Ocio, EM; Rosinol, L; Martinez, R; Teruel, AI; Gutierrez, NC; Bargay, J; Bengoechea, E; Gonzalez, Y; de Oteyza, JP; Gironella, M; Encinas, C; Martin, J; Cabrera, C; Palomera, L; de Arriba, F; Cedena, MT; Paiva, B; Puig, N; Oriol, A; Blade, J; Lahuerta, JJ; San Miguel, JF | Article |
| 2018 | Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. | Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J, GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group | Article |